NYSEARCA:XPH SPDR S&P Pharmaceuticals ETF (XPH) Price, Holdings, & News $57.87 +0.62 (+1.08%) As of 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsShort InterestBuy This Stock About SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get XPH alerts:Sign Up Key Stats Today's Range$56.66▼$57.9550-Day Range$51.36▼$60.7052-Week Range$39.21▼$60.73Volume16,587 shsAverage Volume83,318 shsMarket Capitalization$355.90 millionAssets Under Management$346.59 millionDividend Yield0.64%Net Expense Ratio0.35%Aggregate RatingModerate Buy ETF Overview SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Fund invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. The Pharmaceuticals Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor. Read More SPDR S&P Pharmaceuticals ETF ExpensesTypeXPHHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.56%0.57%0.51%0.53%Other Expenses0.00%0.47%0.55%0.58%0.55%Total Expense0.35%0.74%0.76%0.74%0.73%Fee Waiver0.00%-0.71%-0.64%-0.70%-0.62%Net Expense0.35%0.59%0.63%0.58%0.60% Receive XPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XPH ETF News HeadlinesDitch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?May 19 at 4:19 PM | 247wallst.comTrump to announce discount drug pricing expansion, White House official saysMay 18 at 12:47 PM | reuters.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 21 at 1:00 AM | Brownstone Research (Ad)SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.0610March 23, 2026 | msn.comUS and China clash over fentanyl and tariffs at global drugs meetingMarch 9, 2026 | reuters.comThese 5 Undervalued ETFs Could Be Bargains Right NowFebruary 26, 2026 | 247wallst.comSee More Headlines XPH ETF - Frequently Asked Questions How have XPH shares performed this year? SPDR S&P Pharmaceuticals ETF's stock was trading at $56.01 at the start of the year. Since then, XPH stock has increased by 3.3% and is now trading at $57.87. Who are SPDR S&P Pharmaceuticals ETF's major shareholders? SPDR S&P Pharmaceuticals ETF's top institutional investors include Bank of America Corp DE (13.20%), First Citizens Bank & Trust Co. (3.05%), Cetera Investment Advisers (0.93%) and Private Advisor Group LLC (0.91%). How do I buy shares of SPDR S&P Pharmaceuticals ETF? Shares of XPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SPDR S&P Pharmaceuticals ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that SPDR S&P Pharmaceuticals ETF investors own include NVIDIA (NVDA), Pfizer (PFE), Adobe (ADBE), Applied Materials (AMAT), Chevron (CVX), JPMorgan Chase & Co. (JPM) and Meta Platforms (META). Fund Details IssuerSSgA Fund NameSPDR S&P Pharmaceuticals ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XPH Inception Date6/19/2006 Fund ManagerMichael Feehily, Karl Schneider, Keith Richardson Webwww.spdrs.com Phone+1-617-6644738Fund Focus Asset ClassEquity BenchmarkS&P Pharmaceuticals Select Industry Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings67 Fund Statistics Assets Under Management$346.59 million Average Daily Volume$48.90 thousand Discount/Premium-0.04% Administrator, Advisor and Custodian AdministratorState Street Global Advisors Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerCitadel Options OptionableOptionable Options Volume1 Put Options1 Call Options1 Short Interest436,500 shs Miscellaneous Outstanding Shares6,150,000Beta0.61 Creation Unit50,000 Creation Fee$250.00 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report Top 10 XPH HoldingsOrganon & Co. (NYSE:OGN)Holding Weight: 3.78%Corcept Therapeutics (NASDAQ:CORT)Holding Weight: 2.76%Liquidia (NASDAQ:LQDA)Holding Weight: 2.67%Axsome Therapeutics (NASDAQ:AXSM)Holding Weight: 2.55%Enliven Therapeutics (NASDAQ:ELVN)Holding Weight: 2.50%MBX Biosciences (NASDAQ:MBX)Holding Weight: 2.28%Omeros (NASDAQ:OMER)Holding Weight: 2.25%Trevi Therapeutics (NASDAQ:TRVI)Holding Weight: 2.25%Jazz Pharmaceuticals (NASDAQ:JAZZ)Holding Weight: 2.23%Viatris (NASDAQ:VTRS)Holding Weight: 2.23%Full Holdings DetailsXPH Sector ExposureXPH Industry Exposure This page (NYSEARCA:XPH) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Pharmaceuticals ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
